Credit: Mary Ann Liebert, Inc., publishers
New Rochelle, NY, Sept. 14, 2017–A growing body of clinical evidence shows that transplantation of a patient's own mesenchymal stem cells (MSCs) to achieve a cure and prevent recurrent of Crohn's disease-related fistula can be a safe and effective addition to surgery. A comprehensive review of the latest studies of MSC transplantation for Crohn's fistula and a comparison of MSC versus hematopoietic stem cell (HSC) transplantation is published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Human Gene Therapy website until October 14, 2017.
Fistulas, especially anorectal fistulas, are a common complication of the inflammatory intestinal disorder Crohn's disease. Coauthors Xiao-mei Zhang, Yu-jing Zhang, Wei Wang, Yu-Quan Wei, and Hong-xin Deng, Sichuan University, Chengdu, China, discuss the clinical research supporting the potential for MSC transplantation to improve surgical outcomes, lower the risk of fistula recurrence, and enhance patients' quality of life. In the article entitled "Mesenchymal Stem Cells to Treat Crohn's Disease with Fistula," the authors examine the unique advantages of MSCs, including ease of collection, low immunogenicity when using a patient's own cells for transplant, and the immunoregulatory activity of MSCs.
"Crohn's disease continues to be a major burden on human health despite newer immunomodulatory therapies, and Crohn's-related fistulas are a particularly intractable problem for many patients," says Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Worcester, MA. "This paper demonstrates promising results with mesenchymal stem cells as a novel regenerative medicine approach to this complication. The work could ultimately result in major benefits to many individuals suffering with this disease."
###
About the Journal
Human Gene Therapy the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene and Cell Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies, is an authoritative peer-reviewed journal published monthly in print and online. Led by Editor-in-Chief Terence R. Flotte, MD, Celia and Isaac Haidak Professor of Medical Education and Dean, Provost, and Executive Deputy Chancellor, University of Massachusetts Medical School, Human Gene Therapy presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Its companion journals, Human Gene Therapy Methods , published bimonthly and focused on the application of gene therapy to product testing and development, and Human Gene Therapy Clinical Development," published quarterly, features data relevant to the regulatory review and commercial development of cell and gene therapy products. Tables of contents for all three publications and a free sample issue may be viewed on the Human Gene Therapy website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Nucleic Acid Therapeutics, Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.comPhone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101
Media Contact
Kathryn Ryan
914-740-2250
@LiebertPub
http://www.liebertpub.com
Original Source
http://www.liebertpub.com/global/pressrelease/mesenchymal-stem-cells-offer-novel-treatment-approach-for-crohns-disease-fistula/2251/ http://dx.doi.org/10.1089/hum.2016.095
